在胃癌中准LYAR的治疗潜力
Kai Qin1, Guo-Qiang Chen1, Jing-Wen Ling1,2
1Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Future science OA
|January 9, 2026
概括
在胃癌 (GC) 中,Ly1抗体反应克隆 (LYAR) 被上调,促进瘤生长. 高LYAR表达可能预测对特定AZD药物的敏感性,这表明LYAR是GC的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 胃癌 (GC) 仍然是一个重大的全球健康挑战.
- 识别用于GC诊断和治疗的新生物标志物至关重要.
研究的目的:
- 为了研究Ly1抗体反应克隆 (LYAR) 在胃癌组织中的表达.
- 评估LYAR作为GC的潜在诊断和治疗目标.
- 为了确定潜在的药物向GC中的LYAR敏感性.
主要方法:
- 在20个GC数据集中对LYAR mRNA表达的分析 (1804个GC样本,858个正常组织).
- 使用ROC曲线,灵敏度和特异性评估LYAR的临床和病理相关性.
- 研究上游的转录调节和药物敏感性分析.
主要成果:
- 在GC组织中,LYAR表达显著上调 (SMD: 1.20).
- LYAR显示了高的诊断准确性 (AUC:0.89,敏感性:0.74,特异性:0.89).
- MYC可能会增强LYAR表达,促进GC的进展;高LYAR表达与对AZD化合物的敏感性相关.
结论:
- LYAR过度表达促进了GC的进展和瘤发生.
- LYAR作为潜在的诊断生物标志物和胃癌的治疗点.
- 针对LYAR可能为GC患者提供一种新的治疗策略.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K